Korean drugmakers’ R&D spending falls slightly in 1Q

Published: 2013-06-05 07:00:00

Updated: 2013-06-05 07:00:00

Korea’s 53 listed pharmaceutical companies saw their combined research and development (R&D) spending drop by 7.4 percent to 185.3 billion won, down 0.2 percent points from 7.6 percent a year ago, an online pharmaceutical information provider said yesterday, pointing to their lack of willingness ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK